Advertisement

Header Utility Menu

  • Subscribe
  • Advertise
  • Contact Us
  • Events

LinkedIn Facebook Twitter Instagram Get Our App

  • Login

Virginia Business

Mobile Menu

  • Issues
  • Industries
    • Banking/Finances
    • Law
    • Real Estate
    • Economic Development
    • Education
    • Energy/Green
    • Federal Contracting
    • Government
    • Healthcare
    • Hotels/Tourism
    • Insurance
    • Ports/Trade
    • Small Business
    • Startups
    • Technology
    • Transportation
  • Regions
    • Central Virginia
    • Eastern Virginia
    • Northern Virginia
    • Roanoke/New River Valley
    • Shenandoah Valley
    • Southern Virginia
    • Southwest Virginia
  • Reports
    • Best Places to Work
    • Business Person of the Year
    • CEO Pay
    • COVID-19
    • Generous Virginians Project
    • Legal Elite
    • Most Influential Virginians
    • Maritime Guide
    • Site Locator
    • The Big Book
    • Virginia CFO Awards
  • Company News
    • For the Record
    • People
  • Opinion
  • Lists
  • Awards/Events
    • 2022 Virginia Business Political Roundtable
    • Women in Leadership
    • Diversity Leadership Series
    • Virginia 500
    • Legal Elite
    • CFO Awards
    • Big Book of Lists
    • 100 People To Meet
    • Best Places To Work
  • Virginia 500
    • Read The Issue
    • Power Up Virginia 500
    • Buy an award plaque
    • Suggest execs for 2023

Advertisement

Header Primary Menu

  • Issues
    • January 2023
    • December 2022
    • November 2022
    • October 2022
    • September 2022
    • Issues Archive
  • Industries
    • Banking/Finances
    • Law
    • Real Estate
    • Economic Development
    • Education
    • Energy/Green
    • Federal Contracting
    • Government
    • Healthcare
    • Hotels/Tourism
    • Insurance
    • Ports/Trade
    • Small Business
    • Startups
    • Technology
    • Transportation
  • Regions
    • Central Virginia
    • Eastern Virginia
    • Northern Virginia
    • Roanoke/New River Valley
    • Shenandoah Valley
    • Southern Virginia
    • Southwest Virginia
  • Reports
    • Best Places to Work
    • Business Person of the Year
    • CEO Pay
    • COVID-19
    • Generous Virginians Project
    • Legal Elite
    • Most Influential Virginians
    • Maritime Guide
    • Site Locator
    • The Big Book
    • Virginia CFO Awards
  • Company News
    • For the Record
    • People
  • Opinion
  • Lists
  • Awards/Events
    • 2022 Virginia Business Political Roundtable
    • Women in Leadership
    • Diversity Leadership Series
    • Virginia 500
    • Legal Elite
    • CFO Awards
    • Big Book of Lists
    • 100 People To Meet
    • Best Places To Work
  • Virginia 500
    • Read The Issue
    • Power Up Virginia 500
    • Buy an award plaque
    • Suggest execs for 2023

Home News U.Va. researcher: COVID-19 drug appears to not work well for diabetics

U.Va. researcher: COVID-19 drug appears to not work well for diabetics

Dexamethasone was given to President Trump during virus bout

Published October 23, 2020 by Kate Andrews

Wladek Minor, Harrison distinguished professor of molecular physiology and biological physics at the University of Virginia. Photo by Dan Addison for U.Va. Communications

A University of Virginia physicist researching a drug that can save severely ill COVID-19 patients’ lives has discovered that it may not work well on diabetics, the U.Va. Health System announced this week. As a result, physicians may need to change the drug regimen for some of their sickest patients.

Dexamethasone, a corticosteroid that was given to President Donald Trump during his recent case of the coronavirus, is carried by a protein in the bloodstream known as serum albumin. For people with lower levels of albumin — including people with diabetes and men with low testosterone — the drug may not be able to attack the virus as effectively. Dexamethasone is prescribed only for patients who are receiving extra oxygen, including those on ventilators.

Lead researcher Wladek Minor, Harrison distinguished professor in the U.Va. Department of Molecular Physiology and Biological Physics, worked with a team of biologists, computer scientists and clinicians at the University of South Carolina and in Poland this summer and fall. He says that the connection between dexamethasone, COVID-19 and low albumin levels — determined by studying data from 373 patients at a hospital in Wuhan, China — is just the beginning of the research.

“We found that everybody with low albumin levels died,” Minor said Thursday in an interview with Virginia Business. He explained that having less of the protein in a patient’s bloodstream gives the drug fewer “docks” to bond with, which limits transmission of the drug. In an earlier study of dexamethasone, scientists found that the hormone testosterone binds the same way as dexamethasone to albumin, resulting in lower testosterone levels in men with less albumin. Also, other medications may compete with dexamethasone for the same cargo docks.

In the study, published this week in the scientific journal IUCrJ, the team of scientists saw that Wuhan patients who died had higher than average blood sugar levels — a hallmark of diabetes. Low testosterone levels were previously identified as an indicator of COVID-related deaths among men.

Minor’s team determined that high blood sugar can negatively affect serum albumin’s ability to deliver dexamethasone, which is used for many conditions, including asthma, lung disease, tuberculosis and croup, to calm inflammation. It was approved for medical use in 1961 after being created in 1957.

Dexamethasone is a corticosteroid drug that has helped save some of the sickest COVID-19 patients’ lives, scientists say. Illustration by Marcin Minor

The drug, which has benefited COVID-19 patients who needed additional oxygen according to research released in July, was among several medications given to President Trump during his hospital stay in early October after his oxygen levels dropped to 93%, according to his medical team.

Minor said he did “not want to speculate” about Trump’s treatment and illness. But the team of scientists acknowledge in the study that dexamethasone cannot be given in much higher doses to patients with low albumin levels because of potential side effects that include mood swings, insomnia and blood clots. The drug also is not effective and possibly harmful for less serious cases of COVID-19 because it can suppress the immune system’s effectiveness against the virus, according to an August study published in the Journal of Hospital Medicine.

The 74-year-old Polish researcher says there’s a real challenge for COVID-19 researchers — whether their focus is on developing a vaccine or treatment for those who contract the virus — because “people would like something fast, and it’s incompatible. You need to hire talented people, you have to think about what to do, and this takes time.”

Minor is co-founder of HKL Research, a company that sells software and data tools that he helped develop and were used in the study. “Hundreds of thousands of scientists” are currently engaged in research to cure, treat and prevent the coronavirus, and they need a way to see and compare others’ data, Minor said.

“The grand challenge” is to develop an advanced information system that brings together all of the information, he added. “You have to combine volumes of experiments to have a big picture.”

 

Subscribe to Virginia Business.

Get our daily e-newsletter.

Related Stories

Virginia Business logo

New drug cocktail appears to block COVID among people exposed to virus

U.Va. Health is testing antibody treatment from Regeneron Pharmaceuticals

VHHA partners with new Va.-based company for medical-grade masks

Olivian, founded in March, produces masks domestically

State COVID-19 cases continue to climb

U.Va. model predicts 400,000+ more Va. cases in 2021

Trending

Dollar Tree CEO resigning; former Dollar General CEO to replace him

Rivers Casino Portsmouth opens to big crowds

Framatome CEO retiring; CFO to be promoted

Va. bill aims to reduce mental health stigma for health care workers

Former EAB buildings in Henrico sell for $5.35M

Sponsored Stories

In the New Year, Aim for Better Cybersecurity

4 innovative ways to create capacity

WHERE IS THE SUPPLY CHAIN WHEN YOU NEED IT?

P.A.I.N.T. Your Financial Mountain

5 Benefits of Treasury Management Services from Atlantic Union Bank

Blazing trails in the digital landscape

Advertisement

Advertisement

Trending

Dollar Tree CEO resigning; former Dollar General CEO to replace him

Rivers Casino Portsmouth opens to big crowds

Framatome CEO retiring; CFO to be promoted

Va. bill aims to reduce mental health stigma for health care workers

Former EAB buildings in Henrico sell for $5.35M

Sponsored Stories

In the New Year, Aim for Better Cybersecurity

4 innovative ways to create capacity

WHERE IS THE SUPPLY CHAIN WHEN YOU NEED IT?

P.A.I.N.T. Your Financial Mountain

5 Benefits of Treasury Management Services from Atlantic Union Bank

Blazing trails in the digital landscape

Get Virginia Business directly on your tablet or in your mailbox!

Subscribe to Virginia Business

Advertisement

Advertisement

Footer Primary Menu

  • virginiabusiness.com
  • Subscribe
  • Advertise
  • About Us
  • Contact Us

Footer Secondary Menu

  • Industries
  • Regions
  • Reports
  • Company News
  • Events

Sign Up For Our Newsletter

Sign Up

LinkedIn Facebook Twitter Instagram Get Our App

Privacy Policy Cookie Policy

Footer Utility Menu

Copyright © 2023 Virginia Business. All rights reserved.

Site Maintained by TechArk